Pregnancy in HIV-Positive Patients: Effects on Vaginal Flora by Vallone, Cristina et al.
Hindawi Publishing Corporation
Infectious Diseases in Obstetrics and Gynecology
Volume 2012, Article ID 287849, 4 pages
doi:10.1155/2012/287849
Review Article
Pregnancy in HIV-Positive Patients: Effectson Vaginal Flora
Cristina Vallone,1 GiulianoRigon,1 Valeria Lucantoni,1
Lorenza Putignani,2 and FabrizioSignore1
1Department of Obstetrics and Gynaecology, San Camillo-Forlanini Hospital, Piazza Carlo Forlanini 1, 00151 Rome, Italy
2Parasitology Unit, Bambino Ges` u Children’s Hospital, IRCCS, Piazza Sant’Onofrio 4, 00165 Rome, Italy
Correspondence should be addressed to Fabrizio Signore, fsignore@scamilloforlanini.rm.it
Received 8 February 2012; Accepted 17 March 2012
Academic Editor: Francesco De Seta
Copyright © 2012 Cristina Vallone et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
A high proportion of HIV-infected pregnant women present pathogenic organisms in their lower genital tract. This has been
associatedwiththedevelopmentofpostpartummorbility,HIVtransmissiontothepartnerandoﬀspring,andothergynaecological
conditions, such as cervical dysplasia or cancer. Vaginal ﬂora alterations can range from 47% in Western countries to 89% in Africa
in pregnant HIV-positive patients, much higher than about 20% of the general population. Pathogen organism retrieval is high.
As peripartum complications due to vaginal infections seem higher in HIV-positive patients, accurate investigation and treatment
of such infections are strongly mandatory.
1.Introduction
The classiﬁcation system, drawn by the Centers for Disease
Control and Prevention (CDC) of HIV infection, includes
several gynaecological conditions such as persistent, fre-
quent, or poorly responsive episodes of vaginal candidiasis,
from light to severe cervical intraepithelial neoplasia (CIN),
pelvic inﬂammatory disease (PID), chronic herpes simplex
virus ulcers, and invasive cervical cancer. Three of these
conditions may have a strong impact on pregnancy, namely,
lower genital tract neoplasia, sexually transmitted infections
and vaginitis [1].
Vaginal infections during pregnancy in HIV-positive
patientshavebeendeeplyinvestigatedinsomerecentstudies.
Preliminary data indicate an association between vaginal
infections, and perinatal morbility.
2.MaterialsandMethods
Pertinent international literature was reviewed; however, due
to the scarcity of studies on the matter, a systematic review
resulted very diﬃcult.Wefocusedourattentionespeciallyon
HIV-positive pregnant women. All data concerning vaginal
infections during pregnancy in HIV-positive patients were
thoroughly analysed.
Data concerning lower genital tract intercurrent path-
ogens, risks of infection, perinatal complications of vaginal
infections, risks of associated conditions, eﬀects on obstetric
management, and results of prevention and therapy are
discussed.
We report our preliminary ﬁndings on 54 pregnant HIV
patients. Vaginal cultures were performed during the ﬁrst
and third trimester of pregnancy.
Cultures included tests for chlamydia, mycoplasma gram
positive and negative bacteria, candida. A smear was per-
formed for protozoa identiﬁcation, notably trichomonas.
3. Results and Discussion
3.1. Pathogenic Lower Genital Tract Organisms in HIV Preg-
nancy. A study from a high-risk USA population on 854
HIV-infected women and 434 controls reports that the
prevalenceofbacterialvaginosiswas47%intheHIV-positive
women compared with 44% in the HIV-negative women:
this diﬀerence was not statistically signiﬁcant (P = 0.36)
[2]. After adjustment for other covariates, HIV-positive2 Infectious Diseases in Obstetrics and Gynecology
women were at higher risk of contracting bacterial vaginosis
compared to HIV-seronegative women (odds ratio (OR)
1.31; 95% conﬁdence interval (CI) 1.01–1.70) by Gram’s
stain but not by clinical criteria (OR 1.16; CI 0.87–1.55).
Among HIV-positive women, the use of antiretroviral drugs
was associated with a lower prevalence of bacterial vaginosis
(adjusted OR 0.54; CI 0.38–0.77). These high rates of
bacterial vaginosis are similar to the ones reported in three
studies carried out on women attending sexually transmitted
disease centers (range 12–61%) but are generally higher
compared to healthy pregnant women (range 10–32%).
As t u d yc o n d u c t e di nC a m e r o o nc o m p a r e sﬁ r s tt ri m e s t e r
screening cultures from 198 HIV-positive pregnant patients
to 1810 controls [1]. All lower genital tract infections, except
candidiasis, were more prevalent among HIV-positive com-
pared to HIV-negative women: vaginal candidiasis (36.9%
versus 35.4%; P = 0.678), Trichomoniasis (21.2% versus
10.6%; P<0.001), gonorrhoea (10.1% versus 2.5%; P<
0.001), bacterial vaginosis (21.2% versus 15.2%; P = 0.026),
syphilis (35.9% versus 10.6%; P<0.001), and Chlamydia
trachomatis (38.4% versus 7.1%; P<0.001).
Leroy et al. reported a similar prevalence of vaginal
candidiasis among HIV-infected pregnant women (22.3%)
and noninfected pregnant women (20.1%) [3].
In South Africa a recent study on 418 HIV-infected and
383uninfectedwomendeliveredvaginallyreportsthat54.8%
of women had positive cultures at birth (439/801), more
among HIV-infected patients compared to the uninfected
ones (60% versus 49.1%, P = 0.002) [4].
According to Joao et al., the overall anogenital prevalence
of GBS colonization was 49/158 (31.0%) in a cohort of
HIV-positive pregnant women during the third trimester of
pregnancy [5].
Genital tract infections such as Neisseria Gonorrhoea,
Chlamydia trachomatis, Candida albicans, and Trichomonas
vaginalis infection have been reported to be more common
in HIV-infected women (WHO/RHT/98.24 (World Health
Organization), UNAIDS/98.44 (United Nations Program on
HIV/AIDS)). African studies report a higher incidence of
syphilis in HIV-positive women. Concurrent infection with
syphilis was shown in 33% of HIV-positive pregnant patients
in South Africa, three times higher than the rate in HIV-
seronegative women.
3.2. Reasons for Common Vaginal Infections in HIV Patients.
The prevalence of vaginal candidiasis in HIV-infected
womendependsonCD4count.Burnsetal.reporteda3-fold
increase in vaginal candidiasis among HIV-infected women
with low CD4 counts compared to HIV-infected women
with normal CD4 count during pregnancy [6]. Apart from
Candida spp.,w er e p o r t e da ni n c r e a s ei nt h ep r e v a l e n c eo f
bacterial vaginosis among HIV pregnant women. Bacterial
vaginosis increases susceptibility to HIV infection and other
genital tract pathogens, but it is not clear whether HIV
increases the risk of developing bacterial vaginosis [7].
Potential biological mechanisms for this inter-relation-
ship of sexually transmitted diseases (STDs), vaginal infec-
tion and HIV, include increased shedding of the virus in
genitalﬂuids,recruitmentofHIVtargetcellsorHIV-infected
cellsintothegenitaltractaspartoftheinﬂammatoryprocess,
stimulationofimmuneresponsetoanSTDcausingincreased
viral replication, and disruption of protective epithelial
barriers [8]. Direct evidence on the association of STDs with
HIV was also provided by a large randomized community-
based trial in Tanzania which showed that a better targeted
treatment of STDs can lower HIV incidence by about 40%.
Depletion of lactobacilli may limit the production of
hydrogen peroxide. It has been postulated that low vaginal
pH inhibits CD4 lymphocyte activation and reduces HIV
target cells in the vagina. Elevated vaginal pH may enhance
HIV adherence to vaginal eukaryotic cells.
3.3. Risk of Vaginal Infection in HIV Patients. According
to Mbu et al. [1], there is evidence that the severity of
preinvasive cervical lesion is related to the degree of
immunosuppression, suggesting that it contributes (at least
in part) to the risk of developing preinvasive lesions [9, 10].
Some studies suggest that the high prevalence of preinvasive
cervical lesions may be related to concomitant risk factors
related to the mode of HIV transmission [11]. Ahr et al.
reportedthatHIV-positivewomenwithlowCD4counthada
higher prevalence of human papilloma virus (HPV) and that
preinvasive and invasive cervical lesions of the cervix were
more frequent in women with HPV [12], recognized to be a
causative agent for such lesions.
3.4. Perinatal Complications of Vaginal Infections. As re-
ported in several studies carried out in South Africa, vaginal
pathogens were more common in HIV-infected women.
Women with positive cultures had slightly higher rates of
infectious morbidity than those negative cultures (20.5%
versus 15.2%, P = 0.052). Trichomonas vaginalis and Group
BS t r e p t o c o c c u swere signiﬁcantly associated with sepsis (P =
0.023 and P<0.001, resp.), whereas the presence of Candida
species seemed to be protective (relative risk (RR) 0.69, P =
0.014).
Women with positive cultures had slightly higher rates
of infectious morbidity than those without (20.5% versus
15.2%, P = 0.052). Trichomonas vaginalis and Group B
Streptococcus were signiﬁcantly associated with sepsis [4].
In the past bacterial vaginosis had been considered
strongly related to perinatal complications [8]. A meta-
analysis reported a nonsigniﬁcant association of the treat-
ment of bacterial vaginosis in pregnancy with the reduction
in perinatal mortality [13]. In their review Kenyon et al.
studied the use of antibiotics for preterm premature rupture
of the membrane (pPROM) and underlined a statistically
signiﬁcant 43% reduction in risk of chorioamnionitis (RR =
0.57; 95% CI: 0.37–0.86) [14]. However, there was no
impact on perinatal mortality or fetal death before discharge
(RR = 0.90; 95% CI: 0.74–1.10). Another Cochrane review
by Flenady and King on antibiotics for PROM at or near
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(RR = 0.60; 95% CI: 0.30–1.18) nor on perinatal mortality
(RR = 0.98; 95% CI: 0.14–6.89) [15].
3.5. HPV Infection in HIV-Positive Pregnant Patients. Pap
smears in an African population show that HIV-positive
women are more likely to have preinvasive cervical lesions:
low-grade squamous intraepithelial lesion (SIL) (18.2%
versus 4.4%; P<0.001) and high-grade squamous intraep-
ithelial lesion (12.1% versus 1.5%; P<0.001) [1]. This is an
8-fold increase in high-grade SIL among HIV-infected preg-
nant women compared to their noninfected counterparts.
A 5-fold increase in cervical intraepithelial neoplasia among
HIV-infected women was described in previous studies [16].
3.6. Maternal HIV Seroconversion and Vaginal Infection. A
studybyTahaon1196pregnantwomen,followedantenatally
for a median of 3.4 months, reports that 27 women
seroconverted by the time of delivery [17]. Postnatally, 97
seroconversions occurred among 1169 seronegative women
who were followed for a median of 2.5 years. Bacterial
vaginosis was signiﬁcantly associated with antenatal HIV
seroconversion (adjusted OR = 3.7) and postnatal HIV
seroconversion (adjusted OR = 2.3). The approximate
attributable risk of bacterial vaginosis alone was 23%
for antenatal HIV seroconversions and 14% for postnatal
seroconversions. The same study conﬁrms the ﬁndings of
earlier cross-sectional studies which reported associations
between bacterial vaginosis and HIV among sex workers
in Thailand, rural women in the Rakai district of Uganda,
and urban women in Malawi. The temporal nature of such
associations in this study strengthens the inference that the
relationship between bacterial vaginosis and HIV acquisition
couldbecausal.Gonorrhea,Syphilis,andTrichomoniasiswere
signiﬁcantly associated with HIV seroconversion either in
univariate or multivariate models. Gonorrhea and Syphilis
showed large relative risks, although their incidence and
prevalence rates were not as high as those of bacterial
vaginosis or Trichomoniasis, the latter being associated with
a 2–6-fold increase in risk of HIV transmission [18].
3.7. Treatment and Perinatal Beneﬁts. The use of antisep-
tic or antiviral agents to cleanse the birth canal during
labour and delivery has been hypothesised as a possible
approach to reducing intrapartum transmission of HIV
(WHO/RHT/98.24 UNAIDS/98.44). The eﬃcacy of the use
of chlorhexidine lavage to reduce the transmission of Group
BS t r e p t o c o c c u swas demonstrated in Scandinavian studies.
A Malawian quasirandomised study compared four-hourly
aqueous chlorhexidine 0.25% solution by vaginal swabbing
after vaginal examinations and a chlorhexidine wash for the
baby, with a control group receiving no wash. No overall
reduction was shown in the rate of HIV transmission in
the above study group. There was a signiﬁcant reduction in
transmission in mothers who had ruptured membranes for
more thanfourhours. Signiﬁcant reductions in neonatal and
puerperal sepsis were also seen following this intervention.
Benzalkonium Chloride has been suggested as an alternative
antiseptic agent.
4. Conclusions
It is not clear whether HIV infection increases the risk of
acquisition of vaginal infections, but these conditions are
commonamongsexuallyactivewomen.Sexuallytransmitted
infections (STIs) and preinvasive cervical lesions were found
to be more prevalent among HIV-infected pregnant women
compared to their noninfected counterparts [1]. Even com-
paring African and USA cohorts, HIV pregnant patients
present a higher prevalence of vaginal infections compared
to HIV seronegative. Women with positive vaginal cultures
had slightly higher rates of infectious morbidity than those
without (20.5% versus 15.2%, P = 0.052). Trichomonas vagi-
nalis and Group B Streptococcus were signiﬁcantly associated
with sepsis. There is some evidence of possible beneﬁts due
to the identiﬁcation and treatment of vaginal intercurrent
infection in HIV-positive patients. Perinatal mortality has
not been aﬀected, but some reduction in amnionitis in case
of membrane rupture has been demonstrated [13].
According to WHO guidelines, we believe that HIV-
positive women should undergo a full physical examination
at the ﬁrst visit.
Particular attention has to be paid to any signs of vag-
inal thrush or lymphadenopathy. Clinical diagnosis and
treatment of vaginal or cervical inﬂammation, abnormal
discharge or STD, should be a priority. A cervical smear has
to be performed if this has not been undertaken within the
recent past. Colposcopy should be reserved for women who
have an abnormal cervical smear result.
Prolonged rupture of membranes should be avoided, as
mother-to-child transmission increases where membranes
arerupturedformorethanfourhours[19].Artiﬁcialrupture
of membranes should not be performed if progress of labour
isadequate.Asageneralrule,an yprocedurewhichbreaksthe
baby’s skin or increases the baby’s contact with the mother’s
blood—such as scalp electrodes or scalp blood sampling—
should be avoided unless absolutely necessary. Episiotomy
should not be performed routinely, but reserved for those
cases with an obstetrical indication.
Forceps may be preferable to vacuum extraction, given
the risk of microlacerations of the scalp from the vacuum
cup. There is an increasing evidence that elective caesarean
section may help prevent HIV transmission to the newborn
[20]. The operation carries risks of maternal complications
and is associated with higher postoperative morbidity in
HIV-positive women [21]. Prophylactic antibiotics should
be administered for both elective and emergency caesarean
sections.
The postpartum care of HIV-positive women should be
similar to that for uninfected patients.
HIV-positive women are more prone to postpartum
infectious complications, including urinary tract, chest,
episiotomy, and caesarean section wound infections. All
mothers should be given instructions on perineal care and
the safe handling of lochia and blood-stained sanitary pads
or materials.
Mothers should be counselled on the need for follow-up
care, and advices on contraception systems should be given.4 Infectious Diseases in Obstetrics and Gynecology
On the basis of our preliminary observations, 15 out
of our 54 pregnant HIV-patients showed clinical signs of
vaginitis which was far in excess of the rate in our control
population; a third of the HIV patients developed clinical
vaginitisversusa5%expectedrateinourgeneralpopulation.
Common candida was by far the most represented
pathogen present in almost all cases as a principal or
associated agent.
As a result of our investigation, we can state that in our
population an abnormal vaginal ﬂora in a pregnant HIV-
patient is a very common occurrence. Therefore, a strict
screeningismandatory.Ouraimistoprovidefullbreakdown
of our experience in the near future.
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